Molecular Templates, Inc. (NASDAQ:MTEM) Expected to Post Earnings of -$0.30 Per Share

Equities analysts expect Molecular Templates, Inc. (NASDAQ:MTEM) to report earnings of ($0.30) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Molecular Templates’ earnings, with the highest EPS estimate coming in at $0.10 and the lowest estimate coming in at ($0.71). Molecular Templates reported earnings of ($0.53) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 43.4%. The firm is scheduled to issue its next earnings results on Thursday, March 17th.

According to Zacks, analysts expect that Molecular Templates will report full year earnings of ($1.62) per share for the current year, with EPS estimates ranging from ($2.04) to ($1.22). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.82) per share, with EPS estimates ranging from ($2.27) to ($1.49). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that cover Molecular Templates.

Molecular Templates (NASDAQ:MTEM) last announced its quarterly earnings results on Monday, November 15th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.16). Molecular Templates had a negative net margin of 417.71% and a negative return on equity of 117.50%. The firm had revenue of $2.38 million for the quarter, compared to analyst estimates of $15.69 million.

Several research firms recently weighed in on MTEM. Barclays reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Molecular Templates in a report on Friday, December 3rd. Zacks Investment Research downgraded shares of Molecular Templates from a “buy” rating to a “hold” rating in a report on Friday, November 12th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $12.29.

MTEM stock opened at $3.70 on Friday. The company has a market capitalization of $208.33 million, a P/E ratio of -1.95 and a beta of 1.10. The company has a 50-day simple moving average of $4.18 and a 200 day simple moving average of $5.81. Molecular Templates has a fifty-two week low of $3.30 and a fifty-two week high of $15.19. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.49.

In related news, major shareholder Target N. V. Biotech acquired 200,000 shares of the business’s stock in a transaction on Thursday, January 6th. The shares were purchased at an average price of $4.04 per share, for a total transaction of $808,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 38.20% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in MTEM. Advisor Group Holdings Inc. grew its stake in Molecular Templates by 764.6% during the 3rd quarter. Advisor Group Holdings Inc. now owns 4,349 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 3,846 shares in the last quarter. Citigroup Inc. grew its stake in Molecular Templates by 100.4% during the 3rd quarter. Citigroup Inc. now owns 4,765 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 2,387 shares in the last quarter. Royal Bank of Canada grew its stake in Molecular Templates by 97.7% during the 3rd quarter. Royal Bank of Canada now owns 5,186 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 2,563 shares in the last quarter. BNP Paribas Arbitrage SA grew its stake in Molecular Templates by 374.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 6,757 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 5,333 shares in the last quarter. Finally, Federated Hermes Inc. grew its stake in Molecular Templates by 186.7% during the 2nd quarter. Federated Hermes Inc. now owns 9,088 shares of the biotechnology company’s stock valued at $71,000 after acquiring an additional 5,918 shares in the last quarter. 70.12% of the stock is currently owned by institutional investors.

Molecular Templates Company Profile

Molecular Templates, Inc engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E.

Featured Article: What is the Moving Average Convergence Divergence (MACD) oscillator?

Get a free copy of the Zacks research report on Molecular Templates (MTEM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.